Skip to Content
  • Previous Rank21
  • Revenues ($M)$121,546
  • Revenue Percent Change18.5%
  • Profits ($M)$1,427
  • Profits Percent Change17.4%
  • Assets ($M)$34,122
  • Employees37,300
  • Market Value — as of March 31, 2017 ($M)$25,725

Cardinal Health, a drug wholesaler that also makes gloves and surgical apparel, has been shoring up its future earnings through a series of strategic acquisitions, development of its alternate care business, and promotion of its specialty drug assets. In late 2015 the company acquired Cordis, naviHealth, and Harvard Drug; it spent much of 2016 integrating them, with a 19% increase in annual revenue to show for it. The company’s pharmaceutical segment endured ongoing profit pressures for generics and the loss of a major customer but lessened the blows with new drug launches and sales growth; its medical segment grew because of acquisitions. The partnerships and purchases are a way for Cardinal Health to snag a greater share of the medical products sold to hospitals, physicians, and ambulatory centers. The company was founded in 1979 and is headquartered in Dublin, Ohio.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

George S. Barrett
CEO Title
Chairman & Chief Executive Officer
Wholesalers: Health Care
HQ Location
Dublin, OH
Years on Fortune 500 List23
Figures are for fiscal year ended June 30, 2016.

Cardinal Health Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$121,54618.5%
Profits ($M)$1,42717.4%
Assets ($M)$34,122-
Total Stockholder Equity ($M)$6,554-
Market Value — as of March 31, 2017 ($M)$25,725-

Profit Ratios

Profit as % of Revenues1.2%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity21.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)4.32
EPS % Change (from 2015)19.3%
EPS % Change (5 year annual rate)9.7%
EPS % Change (10 year annual rate)6.4%

Total Return

Total Return to Investors (2016)-17.7%
Total Return to Investors (5 year, annualized)14.5%
Total Return to Investors (10 year, annualized)6.4%